Live Breaking News & Updates on Interline Therapeutics

Stay updated with breaking news from Interline therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Jim Tananbaum, Founder and CEO of Foresite Capital, Announces $173 Million in Funds Raised for Foresite Labs Incubated Companies

Jim Tananbaum, Founder and CEO of Foresite Capital, Announces $173 Million in Funds Raised for Foresite Labs Incubated Companies
lapostexaminer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lapostexaminer.com Daily Mail and Mail on Sunday newspapers.

United States , San Francisco , Jim Tananbaum , Vikram Bajaj , Tensixteen Bio , Harvard Business School , Geltex Pharmaceuticals , Foresite Capital Fund , Google Life Sciences , Foresite Capital , Foresite Labs , Interline Therapeutics , Sestina Bio , Google Life , Applied Mathematics , Electrical Engineering ,

Vikram Bajaj, PhD: "Innovation Doesn't Come from Boston and San Francisco Alone"

Vikram (Vik) Bajaj, CEO and co-founder of Foresite Labs, recently discussed Foresite Labs and its approach to incubating data-driven drug developers, platform companies, and healthcare startups with GEN Edge: ....

Vik Bajaj Foresite , Vikram Vik Bajaj , Vik Bajaj Foresite Labs , Managing Partner , Foresite Capital , Esker Therapeutics , Interline Therapeutics , Sestina Bio ,

Interline Will Focus $92 Million Investment to Advance Precision Medicine Platform


Published: May 14, 2021
By Brandon May
Foresite Labs-incubated company Interline Therapeutics 
announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners. The funding, which has officially launched the company, will be geared toward the development of therapies that correct dysfunctional protein communities to treat various diseases. 
The $92 million financing round is a combination of seed and Series A funding. The newly launched company says the proceeds will be funneled to facilitate the expansion of its research platform and advance a total of six preclinical therapeutic programs. 
Interline Therapeutics will specifically use genomics, proteomics, structural biology, and computational chemistry to “map and modulate protein communities” to construct a precision medicine platform focused on genomics, protein communities, and modulators of these communities. These three pillars ....

United States , San Francisco , Kinnate Biopharma , Warburg Pincus , June Lee , Vikram Bajaj , Zachary Sweeney , University Of California , Interline Therapeutic Co , Memorial Sloan Kettering Cancer Center , Interline Therapeutics , Foresite Capital , Memorial Sloan Kettering Cancer , Therapeutic Co Founder , Chief Executive Officer , Denali Therapeutics , Foresite Labs Incubated , San Francisco Based Esker Therapeutics , Foresite Labs , Orbimed Asia Partners , Orbimed Private , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , வார்பர்க் பிங்கஸ் , ஜூன் லீ , விக்ரம் பஜாஜ் ,